title: [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].
abstract: During the last two decades, improvements in the induction and consolidation treatment phases in patients with high-risk neuroblastoma have not translated into significant increases in survival rates. Efforts to improve outcome have used high-dose chemotherapy with stem cell rescue and more recently, differentiating (retinoids) and antiangiogenic agents. In parallel, immunotherapy has become an increasingly important part of the treatment of high-risk neuroblastoma. We review here the biological concepts underlying these new approaches and their clinical applications, with a particular emphasis on applications that manipulate the immune system, including monoclonal antibodies, gene-modified tumor cells (vaccines) or immune effectors.
authors.affiliation: Service de pédiatrie, Centre Léon Bérard, Lyon, France. roussea@lyon.fnclcc.fr
authors.forename: Raphaël
authors.initials: R
authors.lastname: Rousseau
authors.forename: Valérie
authors.initials: V
authors.lastname: Combaret
authors.forename: Eric
authors.initials: E
authors.lastname: Yvon
authors.forename: Matthias
authors.initials: M
authors.lastname: Schell
authors.forename: Irène
authors.initials: I
authors.lastname: Philip
authors.forename: Alain
authors.initials: A
authors.lastname: Puisieux
authors.forename: Didier
authors.initials: D
authors.lastname: Frappaz
authors.forename: Thierry
authors.initials: T
authors.lastname: Philip
authors.forename: Christophe
authors.initials: C
authors.lastname: Bergeron
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D011379:Prognosis